©The Author(s) 2025.
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 100167
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100167
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100167
Table 4 Adverse events of patients at third-line chemotherapy, n (%)
| Any grade | Grade 3 or more | |
| Fatigue | 51 (36.2) | 16 (11.3) |
| Vomiting | 38 (27.0) | 14 (9.9) |
| Bone marrow suppression | 26 (18.4) | 2 (1.4) |
| Anorexia | 20 (14.2) | 2 (1.4) |
| Peripheral neuropathy | 18 (12.8) | 10 (7.1) |
| Diarrhea | 16 (11.3) | 5 (3.5) |
| Constipation | 13 (9.2) | 4 (2.9) |
| Skin rash | 1 (0.7) | 0 (0) |
- Citation: Kim B, Kim J, Yang S, Ahn J, Jung K, Lee JC, Hwang JH. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. World J Gastrointest Oncol 2025; 17(2): 100167
- URL: https://www.wjgnet.com/1948-5204/full/v17/i2/100167.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i2.100167